Exploring the future of non-small cell lung cancer treatment.
Ramalingam
Suresh
S
Department of Medicine, Division of Medical Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D009154:Mutation; D015398:Signal Transduction; D014481:United States
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors